First quantity, then quality. China is now at the quality step, where its research institutions are surging in the world rankings. The US is just trying to cling to its lead where it still has one; it's not opening up any distance. This is once again, just like before, a place where you need to look at the evidence of what's actually happening rather than clamp down stubbornly on an imaginary worst-case scenario unsupported by recent events. There is truly no support in this picture for pessimism of China's scientific and technological future. Here are some articles that document the rise in quality of Chinese institutions:
Nature Index launched its
2018 rising stars ranking that distinguishes emerging universities and institutes that make scientific research;
fifty-one of the top 100 are from China.
The research produced by universities and institutes in China is increasing exponentially. An
undertaken by Times Higher Education believes that by 2022 China could dethrone the United States in scientific research and consequently become one of the most innovative nations in the world.
Top 10 Nature Index Rising Stars 2018
- University of the Chinese Academy of Sciences - China
- Tsinghua University - China
- Shanghai Jiao Tong University - China
- Southern University of Science and Technology - China
- Wuhan University - China
- University of Science and Technology of China - China
- Indian Institutes of Technology - India
- Nanjing University - China
- South China University of Technology - China
- Southeast China University - China
Chinese institutions continue to rise in Nature Index
Xinhua | Updated: 2018-06-07
LONDON - The Chinese Academy of Sciences (CAS) is at the top place among the world's leading institutions for high-quality scientific research, according to the Nature Index 2018 annual tables released on Thursday.
As for the specific sector of academic institutions, China's Peking University and Tsinghua University makes it into the global academic top 10. Meanwhile, Nanjing University has climbed from 21 to 13, and the University of Science and Technology of China has made its way to 18, from 27.
Overall, almost 90 percent of the 83 academic institutions from China in the top 500 have improved their positions in the last year, compared to just about 45 percent of the 135 from the United States.
(same report)
However, one question that always emerges when China’s rise is discussed is whether wrongdoing or game-playing has distorted the picture. For example, China has been involved in some of the most high-profile and widespread examples of suspected peer review fraud that have been uncovered in recent years. Typically, such fraud occurs when the email addresses of the authors’ suggested peer reviewers turn out to be controlled by the authors themselves or by companies connected to them. In April 2017, more than 100 Chinese-authored papers were retracted en masse by the journal Tumor Biology after editors found “strong reason to believe that the peer review process was compromised”. And according to data from Retraction Watch and published by the website Quartz in 2017, Chinese-authored papers accounted for more than half of the retractions for fake peer review between 2012 and 2016, while Taiwan accounted for another 15 per cent – the second highest amount. However, at 276 and 73 papers out of a total of 502 papers, it is only fair to note that the detected cases of fake peer review accounted for a minuscule proportion of the 9.3 million pieces of research published during the five years in question, according to Scopus.
Chinese research faces other issues, too. Plagiarism concerns are never far from the headlines, while Times Higher Education has uncovered examples of Chinese institutions making large cash offers to Western researchers in return for listing the institution on their papers, in an apparent attempt to improve their rankings. However, it is very difficult to determine the true extent of any of these practices. Ivan Oransky, founder of Retraction Watch, says that while “in many ways fake peer review is the easiest to [spot]”, China has “many, many other problems”. He, too, is unsure of their overall impact, but believes that it is important to look at the incentives that Chinese researchers are given. “There are a few things that happen in China that either don’t happen elsewhere, or happen on a smaller scale,” he says. One example is the bonuses offered for publishing in journals with a high impact factor. Another is the promotions for Chinese clinicians who publish. “So it is like publish or perish on steroids. What that has given rise to…is that organised crime has realised that there is potential here,” Oransky says. This has led to companies sprouting up in China “that may claim to be doing something very legitimate but actually aren’t”. He gives the example of companies that write manuscripts for researchers and then also go on to sell those manuscripts to other researchers for submission to different journals under their own names.
Oransky says that the fixation on whether China is overtaking the US on research volume – which in his view is an “irresponsible” way to assess relative performance – does not help matters. “I’m sure the Chinese government loves that, so it is going to create incentives for people to publish more papers,” he warns. For Rui Yang, associate dean for cross-border and international engagement at the University of Hong Kong, the high-profile episodes of fraud have a knock-on effect for Chinese science that will harm it in the long run. “The immediate effect is that international circles [lose] trust in China’s research, and scholars are no longer keen to work with Chinese colleagues,” he points out.
This reputational risk is not lost on the Chinese government. It came down hard on the more than 400 academics implicated in the Tumor Biology case and, last year, announced a range of reforms designed to clamp down on academic misconduct. The recording of instances in a national database could lead to the researchers involved being blacklisted and prevented from accessing future funding or jobs. Nicholas Steneck, an expert in research integrity at the University of Michigan, says it is “too early to tell” if China’s crackdown will bear fruit. But, he adds, when assessing the impact of misconduct on Chinese research it is also important to remember that the problems are not confined to China. “It certainly would help if publication incentives were more realistic, but that is true in most countries,” he says. “Globally, there is too much misconduct in research. No country can sit back and say: ‘We are doing a good job.’”
He concedes that the difficulty of controlling China’s gigantic research system means that it “may have more questionable publications than other countries. But it also does excellent research based on high standards of integrity. I think China should be given a chance to show that it is making a sincere effort to improve integrity.” Other observers suggest that the more closely China becomes involved in increasingly globalised scientific collaboration networks, the more its researchers will, of their own accord, strive to adhere to international standards. And this trend will only be furthered by the huge numbers of Chinese academics being trained abroad, they add. William Kirby, Chang professor of China studies at Harvard University, says that “any place where there is enormous pressure to publish – and that is certainly true in China…[imposes] pressures for people to bend professional norms. So that is a worry, but I don’t think that is a particularly significant worry in the long run because of the growing strength of professional oversight…and because of the strength of international standards.”